Verici Dx (LSE:VRCI) Beta: 0.3190 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Verici Dx Beta?

Verici Dx LSE:VRCI Beta is 0.3190 as of Jul. 23, 2026. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-23), Verici Dx's Beta is 0.3190.

Verici Dx  (LSE:VRCI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Verici Dx Beta Related Terms

Verici Dx Beta Historical Data

* Premium members only.

The historical data trend for Verici Dx's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Beta Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.12 0.33 -0.37

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.12 0.02 0.33 0.36 -0.37

LSE:VRCI vs TMO, DHR, IDXX: Beta Comparison

For the Diagnostics & Research subindustry, Verici Dx's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx Beta vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Beta distribution charts can be found below:

* The bar in red indicates where Verici Dx's Beta falls into.


Verici Dx Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3190 mean?
Verici Dx (LSE:VRCI) has a Beta of 0.3190 as of Jul. 23, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Verici Dx and its competitors.
Is Verici Dx's Beta too high?
Verici Dx's current Beta is 0.3190.
How does Verici Dx's Beta compare to TMO and DHR?
Verici Dx's Beta of 0.3190 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Diagnostics & Research company?
A good Beta depends on the Medical Diagnostics & Research industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Verici Dx and its competitors. Verici Dx's current Beta is 0.3190. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current Beta of 0.3190. The current Beta is 0.3190. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current Beta is 0.3190 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Verici Dx Business Description

Other Exchanges 63V:Germany
Address 19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.